Ouchi et al. [58] reported that microglial activation and dopaminergic terminal loss declined in parallel in the affected nigrostriatal pathway in early PD, as measured with the DAT radiopharmaceutical [11C]-2-β-carbomethoxy-3β-(4-fluorophenyl) tropane [11C]-CFT. Here, SLC6A3 is linked to Parkinson disease.